SecBot SecBot
6-K ·Filed Aug 10, 2026

PPBT

PURPLE BIOTECH LTD.
NEUTRAL
Impact 4/10
Horizonmonths Processed3mo ago SEC0001213900-26-087226
Notable filing: 6-K
Actionable Insight • Neutral

Monitor for IND submission and Phase 1 trial initiation in 2027, which are the next key catalysts. The $6.1M cash runway is tight for a pre-revenue biotech, so watch for potential dilutive financing events.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.55
T+0 close · Aug 10, 2026 · via day close
Latest settled
−21.61%
T+60 · $1.22
Vs SPY
−21.13%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 11 $1.55entry
  2. T+1 · 3mo ago −4.52%α −4.77% · $1.48
  3. T+5 · 3mo ago +0.65%α +1.05% · $1.56
  4. T+20 · 2mo ago +18.71%α +19.77% · $1.84
  5. T+60 · 13d ago −21.61%α −21.13% · $1.22
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Purple Biotech filed an updated corporate presentation on Form 6-K, highlighting its CAPTN-3 tri-specific antibody platform and lead candidate IM1240, which is expected to enter the clinic in 2027. The company reported cash of $6.1M as of June 30, 2026, with a runway to mid-2027. The filing is a routine business update with no new material financial data or clinical results, but the cash runway and pre-revenue status are notable risks for a $2M market cap company.

Key Facts

  • Cash of $6.1M as of June 30, 2026, with runway to mid-2027.
  • Lead program IM1240 (cappedCD3x5T4xNKG2A) expected to enter the clinic in 2027.
  • Pre-IND meeting completed; IND submission planned for 2027.
  • Second program IM1305 (cappedCD3xTROP2xNKG2A) in preclinical development.
  • Market cap of $2M as of filing date.

Financial Impact

Cash of $6.1M provides runway to mid-2027; no revenue reported.

cash

Risk Factors

  • Cash runway only to mid-2027, requiring additional financing before clinical data.
  • All programs are preclinical or early clinical, with no approved products or revenue.
  • Low market cap ($2M) increases volatility and risk of delisting.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-087226
Document: ea0301142-6k_purple.htm0001213900-26-087226
Document: 0001213900-26-087226-index-headers.html0001213900-26-087226
Document: 0001213900-26-087226-index.html0001213900-26-087226
Document: 0001213900-26-087226.txt0001213900-26-087226

Track record

14 reports on PPBT

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 12, 20264d ago SC 13G Neutral 3/10 Entry $1.56 Now $1.68 +7.69% settles Feb 10
  2. Nov 12, 20265d ago EFFECT Neutral 3/10 Entry $1.56 Now $1.68 +7.69% settles Feb 10
  3. Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $1.49 Now $1.68 +12.75% settles Feb 9
  4. Oct 29, 202618d ago Press Release Neutral 3/10 Entry $1.09 Now $1.68 +54.13% settles Jan 27
  5. Oct 5, 20266w ago 6-K Neutral 2/10 Entry $1.47 Now $1.68 +14.29% settles Dec 31
  6. Sep 9, 20269w ago 6-K Neutral 2/10 Entry $1.74 Now $1.68 −3.45% settles Dec 4
  7. Sep 2, 202610w ago 6-K Neutral 3/10 Entry $1.98 Now $1.68 −15.15% settles Nov 27
  8. Aug 10, 202614w ago 6-K Neutral 4/10 Viewing Entry $1.55 to $1.22 Now $1.68 +8.39% ▼ −21.61% −21.13% vs SPY
  9. Aug 7, 202614w ago 6-K Neutral 4/10 Entry $1.43 to $1.22 Now $1.68 +17.48% ▼ −14.69% −12.55% vs SPY
  10. May 15, 202626w ago Press Release Neutral 4/10 Entry $3.94 to $1.55 Now $1.68 −57.36% ▼ −60.66% −65.18% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026